Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajay K Nooka

Showing results (81-90 of 150) with videos related to

Pageof 15
Sort By:
British Journal of Haematology|February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trialVania Hungria, Meral Beksac, Katja C Weisel, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 3, 2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTORMaria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, et al.
The Oncologist|July 7, 2023
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the SoutheastChloe S Lalonde, Jeffrey M Switchenko, Madhusmita Behera, et al.
Leukemia & Lymphoma|May 16, 2014
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphomaLoretta J Nastoupil, Pareen J Shenoy, Alex Ambinder, et al.
Cancer|November 28, 2018
Safety and survival outcomes for bloodless transplantation in patients with myelomaNisha S Joseph, Jonathan L Kaufman, Lawrence H Boise, et al.
Nature Communications|April 25, 2019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosisBenjamin G Barwick, Paola Neri, Nizar J Bahlis, et al.
The Journal of Clinical Investigation|August 5, 2025
Early CD4+ T-cell proliferative burst and chronic T-cell engagement impact myeloma outcomes following T-cell engager therapyAlyssa M Duffy, Anshika Goenka, Maryam I Azeem, et al.
NPJ Vaccines|October 28, 2024
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Research Square|October 4, 2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Pageof 15

Showing results (81-90 of 150) with videos related to

Sort By:
Pageof 15
British Journal of Haematology|February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trialVania Hungria, Meral Beksac, Katja C Weisel, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 3, 2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTORMaria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, et al.
The Oncologist|July 7, 2023
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the SoutheastChloe S Lalonde, Jeffrey M Switchenko, Madhusmita Behera, et al.
Leukemia & Lymphoma|May 16, 2014
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphomaLoretta J Nastoupil, Pareen J Shenoy, Alex Ambinder, et al.
Cancer|November 28, 2018
Safety and survival outcomes for bloodless transplantation in patients with myelomaNisha S Joseph, Jonathan L Kaufman, Lawrence H Boise, et al.
Nature Communications|April 25, 2019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosisBenjamin G Barwick, Paola Neri, Nizar J Bahlis, et al.
The Journal of Clinical Investigation|August 5, 2025
Early CD4+ T-cell proliferative burst and chronic T-cell engagement impact myeloma outcomes following T-cell engager therapyAlyssa M Duffy, Anshika Goenka, Maryam I Azeem, et al.
NPJ Vaccines|October 28, 2024
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Research Square|October 4, 2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Pageof 15